

Freedom of Information Request	FOI 23-324	17 th July 2023
--------------------------------	------------	----------------------------

I am writing to request information regarding the treatment of Hidradenitis Suppurativa. Please see the question below:

Q. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS), with each of the following biologic drugs:

The Health Board is unable to provide information on the number of patients treated with specific drugs. However, please find below the quantities dispensed across Health Board pharmacies for Dermatology and for any medical condition, for the period April 2023 – June 2023:

Biologic Drug	Quantity
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	209
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack	20
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	2
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack	79
INFLIXIMAB (REMICADE) 100 mg Intravenous Infusion 1 Vial Pack	20
SECUKINUMAB (COSENTYX) 150 mg in 1mL Pre-Filled Pen 2 Pre-Filled Pen Pack	6
SECUKINUMAB (COSENTYX) 150 mg in 1mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	2
SECUKINUMAB (COSENTYX) 300 mg in 2mL Pre-Filled Pen 1 Pre-Filled Pen Pack	66
USTEKINUMAB (STELARA) 45 mg in 0.5mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	19
USTEKINUMAB (STELARA) 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	17